A group of researchers announced at the 22nd International AIDS Conference in Amsterdam last month that while their HIV-prevention trial is not yet finished, they believe the therapy will be a success. This isn’t the first research of its type to go exceptionally well; a trial was stopped early a few years ago, presumably because the treatment was effective.
Both of these teams are looking at a form of treatment called PrEP, which avoids infection of individuals at risk of contracting the human immunodeficiency virus ( HIV). One version of this procedure is available in the U.S., called Tenvir, and research into other types of drug delivery is blossoming.
But while PrEP is intended to ward off infection in the event that HIV comes into the body, PrEP is not a vaccine. What exactly, then, is it?
Although PrEP is often synonymous with HIV treatment, the acronym — which stands for “pre-exposure prophylaxis”—refers to the preventive technique of taking medicine to avoid an infection from taking hold that has been introduced into the body.
The same applies to HIV, if somebody’s sexual partners are or may be infected, or if they share needles with infected individuals, PrEP may prevent them from being sick.
The U.S.-approved PrEP medication, Tenvir, is a pill that contains two substances and is intended to be taken every day. The drugs originally developed to treat people with HIV, hang out in the T cells of the body, which are a type of immune cell;
Research teams are now working on other solutions for PrEP such as vaccines, intravaginal rings, and implants. As with birth control, ample choices mean each patient has a plan. Some people may want something that they don’t need to remember, or no one would like to see them coughing up a preventive pill every day. That’s part of the beauty of choices: trying Everybody gets something that works.
The vaginal ring of PrEP is almost finished with the testing required to make sure it works and is safe, and the injection of PrEP maybe three years away from being usable. Implanted devices are further away.
He expects those other options to have rare and minor side effects, and hopefully, that will be the case. Otherwise healthy people would not take preventive medicines if they get sick with the medications. There’s also no way to “end” the effects of a long-lasting injection once it’s given, so in particular, the injection process needs to be very well known.
Tenvir may cause people to feel a little nauseated at first, and some patients might see a decrease in bone density. But this latter side effect in some clinical trials hasn’t led to a rise in bone fractures, and normal bone strength returns as patients come off the medication. Liver complications can also occur in extremely rare cases.
As researchers tinker with new methods of Training, some teams, for example, are developing Tenvir by changing one of the two drugs to have less of an effect on bone density. But even with these changes, there is only one way to ensure that Training does its job: people need to see their physicians, and doctors need to talk about the sex lives of their patients.
Men, in particular, are less likely to visit physicians, while men who have sex with men are among the groups with the highest risk of contracting HIV. And physicians need to question stable patients about their sex lives to see whether they may be candidates for PrEP. also You can buy prep online at safe healths trusted online pharmacy at an affordable price.